Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

NB003

GISTAR-1

Ningbo Newbay Technology Development · Phase 2/3 · Recruiting · Enrollment 255

NCT07379047

Catalyst Primary completion. 08.01.2028. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmReported safety
NB003 15 mg BID (Part 1)n/r
Regorafenib 160 mgn/r

A count stays a count. This page does not turn a count into a percent.